CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) Prasugrel versus clopidogrel in patients with acute coronary syndromes Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Dual antiplatelet therapy: how, how long, and in which patients? Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial
|<<... 3 4 5 6 7 8 9 ...>>|

Clinical Trial2020 May 14. [Epub ahead of print]

JOURNAL：Catheter Cardiovasc Interv. Article Link

Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY

U Baber, R Chandiramani, R Mehran et al. Keywords: stent comparation; DES; bioabsorbable; durable polymer; high-risk patients

ABSTRACT

BACKGROUND - Data examining the safety and efficacy of the bioabsorbable polymer (BP) drug‐eluting stent (DES) as compared with durable polymer (DP) DES in high‐risk patients undergoing percutaneous coronary intervention (PCI) remain limited.

 

METHODS - We conducted a pre‐specified analysis among patients enrolled in the TWILIGHT trial treated with the SYNERGY BP‐DES or a DP‐DES. Following successful PCI and 3 months of ticagrelor plus aspirin, patients were randomized to aspirin or placebo for 1 year; DES choice was at physician discretion. The primary endpoint was target lesion failure (TLF) [composite of cardiac death, target vessel myocardial infarction (MI), clinically driven target lesion revascularization (TLR) or definite/probable stent thrombosis (ST)].

 

RESULTS - Among enrolled participants (N = 9006), 653 were treated exclusively with the SYNERGY BP‐DES and 6404 with a comparator DP‐DES. Over 15 months, TLF rates were 6.4% and 6.1% among those receiving a SYNERGY BP‐DES and a DP‐DES, respectively (adjusted HR 0.93; 95% CI 0.64 – 1.35; p = 0.72). The effect of ticagrelor monotherapy on Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding and the composite of all‐cause death, MI or stroke was uniform across DES groups (both pint >0.10).

 

CONCLUSIONS - The safety and efficacy profile of the SYNERGY BP‐DES is comparable to that of contemporary DP‐DES in high‐risk patients undergoing PCI. Compared to ticagrelor plus aspirin, the effect of ticagrelor monotherapy is consistent among patients receiving SYNERGY BP‐DES or DP‐DES.

 

This article is protected by copyright. All rights reserved.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top